Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T23807 |
BMS-955176 TFA
BMS 955176,GSK-3532795,BMS955176,BMS-955176,GSK3532795 |
||
GSK3532795 is an orally active inhibitor of HIV-1 maturation. GSK3532795 combines broad coverage of polymorphic viruses (EC50: 15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic pro | |||
T69986 |
BMS-955176 HCl
|
||
GSK-3532795 is a second generation inhibitor of hiv-1 maturation, exhibiting a broader spectrum of antiviral effect in vitro and in clinical studies than the prototypical maturation inhibitor bevirimat | |||
T11494 |
GSK3532795
BMS-955176 |
Others | Others |
GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370). |